Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics Inc (NQ: ARQT )

10.24 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 40
Open 10.24
Bid (Size) 10.24 (3)
Ask (Size) 10.70 (3)
Prev. Close 10.24
Today's Range 10.24 - 10.24
52wk Range 1.760 - 13.17
Shares Outstanding 50,241,789
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+198.54%
+198.54%
1 Month
+22.78%
+22.78%
3 Month
+23.08%
+23.08%
6 Month
+12.78%
+12.78%
1 Year
+444.68%
+444.68%

More News

Read More
Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Assessing Arcutis Biotherapeutics: Insights From 4 Financial Analysts
Via Benzinga
Peeling Back The Layers: Exploring Arcutis Biotherapeutics Through Analyst Insights
Via Benzinga
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4
Via Benzinga
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Biotherapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
CAVA Group Posts Strong Q2 Results, Joins Bilibili, Workday And Other Big Stocks Moving Higher On Friday
Via Benzinga
Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session
Via Benzinga
CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
ARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
7 Biotech Stocks to Keep on Your Clinical Radar
Via InvestorPlace
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years
Via Benzinga
Exposures Product Safety
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS